Advances in liquid biopsy-based markers in NSCLC.

Area of Science:

• Oncology
• Molecular Diagnostics
• Biomarker Discovery

Background:

• Lung cancer is a leading cause of cancer death globally, with non-small cell lung cancer (NSCLC) being the most common type.
• Early diagnosis of NSCLC is crucial for improving patient prognosis and survival rates.
• Current diagnostic tools lack sufficient sensitivity for early-stage NSCLC detection.

Purpose of the Study:

• To review recent advancements in liquid biopsy for NSCLC diagnosis and management.
• To highlight the clinical applications of circulating tumor-derived components as early biomarkers for NSCLC.

Main Methods:

• Review of current literature on liquid biopsy techniques in NSCLC.
• Focus on cell-free DNA (cfDNA), circulating tumor cells (CTCs), cell-free RNAs (cfRNAs), and exosomes.
• Analysis of their role in early diagnosis, treatment selection, therapy monitoring, and prognosis assessment.

Main Results:

• Liquid biopsy enables the analysis of circulating tumor-derived components like cfDNA, CTCs, cfRNAs, and exosomes.
• These components show potential as sensitive biomarkers for early NSCLC detection.
• Advances in liquid biopsy facilitate improved treatment selection and prognosis assessment for NSCLC patients.

Conclusions:

• Liquid biopsy represents a significant advancement in the early detection and management of NSCLC.
• cfDNA, CTCs, cfRNAs, and exosomes are key components for developing novel diagnostic and prognostic tools for NSCLC.
• Further research and clinical validation are essential to fully integrate liquid biopsy into routine NSCLC care.